Amycretin
Also known as: NNC0487-0111, NN9487, NN 9487
Classification
Peptide
Regulatory Status
Overview
Amycretin is described as a unimolecular dual agonist combining GLP-1 receptor and amylin receptor activity intended to reduce appetite and body weight. Clinical development is ongoing; it is not an approved medicine.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
ClassB source cannot establish canonical regulatory or safety fields. The statements below are retained as uncertainty, not as a label-backed verdict. | Regulatory status: not-established | Contraindication: No approved label; not for use outside authorized trials. Class concerns for GLP-1/amylin agonists include serious GI intolerance and other labeled class risks of related approved agents. | Warning: Early trials report high rates of gastrointestinal adverse events (nausea, vomiting, diarrhea). | Warning: Gray-market research vials are not approved drug products; identity and sterility are uncertain and injection risk applies. | Precaution: Prescription-only investigational status; do not treat vendor research chemicals as equivalent to trial drug. | Adverse effect: nausea | Adverse effect: vomiting | Adverse effect: diarrhea | Serious adverse effect: severe GI intolerance; other serious risks not fully characterized outside early-phase programs
Pathways
Interactions & cautions
Drug interactions
other GLP-1 receptor agonists, dual agonists, or amylin analogs — Additive GI adverse effects and overlapping metabolic pathways are expected class risks; no approved combination labeling exists. (high)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.